Abstract
Programmed cell death (apoptosis) occursregularly during normal growth and development of themammary gland. One of the most dramatic examples ofapoptosis is evident during the remodeling of the breast that accompanies postlactational involution.Transgenic mouse models have demonstrated thatoverexpression of polypeptides such as transforminggrowth factor alpha (TGFα)3 and insulinlike growth factor I (IGF-I) can block this remodeling, suggestingthat these growth factors may be acting as survivalfactors for the mammary epithelium. In contrast,transgenic mice that overexpress the growth inhibitor transforming growth factor beta (TGF-β)show increased apoptosis in the mammary epitheliumthroughout mammary development, suggestive of amechanism working to counterbalance the survivalfactors. Experiments with mammary epithelial cell lines cultured invitro have confirmed that these growth factors canindeed regulate apoptosis and survival in mammaryepithelial cells; EGF, IGF-I, and basic fibroblastgrowth factor (bFGF) act as survival factors formammary epithelial cells, while TGF-β induces theirdeath. In breast cancer, cytotoxic drugs and hormoneablation increase the expression of TGF-β, which may function to induce cell death by eitherparacrine or autocrine mechanisms. Lastly, although ithas very limited expression in the breast, TNFαhas been shown to be effective in the rapid, direct induction of cell death in breast cancer celllines. Together, these studies describe a complexdynamic pattern of cell death-inducing and survivalfactors that promote the development of the maturemammary gland and that rapidly remodel the tissue afterlactation.
Similar content being viewed by others
REFERENCES
J. F. R. Kerr, A. H. Wylie, and A. R. Currie (1972). Apoptosis: A basic biological phenomenon with wide ranging implications in tissue kinetics. Brit. J. Cancer 26:239–257.
A. H. Wylie, J. F. R. Kerr, and A. R. Currie (1980). Cell death, the significance of apoptosis. Int. Rev. Cytol. 68:251–306.
D. J. P. Ferguson and T. J. Anderson (1981). Ultrastructural observations on cell death by apoptosis in the “resting” human breast. Virchows Arch Path. Anat. 393:193–203.
D. J. P. Ferguson and T. J. Anderson (1981). Morphological evaluation of cell turnover in relation to the menstrual cycle in the “resting” human breast. Brit. J. Cancer 44:177–181.
T. J. Anderson, D. J. P. Ferguson, and G. M. Raab (1982). Cell turnover in the “resting” human breast: Influence of parity, contraceptive pill, age and laterality. Brit. J. Cancer 46: 376–382.
N. I. Walker, R. E. Bennet, and J. F. R. Kerr (1989). Cell death by apoptosis during involution of the lactating breast in mice and rats. Am. J. Anat. 185:19–32.
R. Strange, F. Li, S. Saurer, A. Burkhardt, and R. R. Friis (1992). Apoptotic cell death and tissue remodeling during mouse mammary gland involution. Development 115:49–58.
R. Strange, R. R. Friis, L. T. Bemis, and F. J. Geske (1995). Programmed cell death during mammary gland involution. Methods Cell Biol. 46:355–368.
R. Pinkas-Kramarski, I. Alroy, and Y. Yarden (1997). ErbB receptors and EGF-like Ligands: Cell lineage determination and oncogenesis through combinatorial signaling. J. Mam. Gland Biol. Neoplasia 2:97–107.
J. A. Schroeder and D. C. Lee (1998). Dynamic expression and activation of ERBB receptors in the developing mouse mammary gland. Cell Growth Differ. 9:451–464.
J. Sebastian, R. G. Richards, M. P. Walker, J. F. Wiesen, Z. Werb, R. Derynck, Y. K. Hom, R. R. Cunha, and R. P. DiAugustine (1998). Activation and function of the epidermal growth factor receptor and erbB-2 during mammary gland morphogenesis. Cell Growth Differ. 9:777–785.
G. Carpenter (1980). Epidermal growth factor is a major growth promoting agent in human milk. Science 210:198–199.
J. M. Beardmore and R. C. Richards (1983). Concentrations of epidermal growth factor in mouse milk throughout lactation. J. Endocrinol. 96:287–292.
N. J. Kenney and R. B. Dickson (1996). Growth factor an sex steroid interactions in breast cancer. J. Mam. Gland Biol. Neoplasia 1:189–198.
E. P. Sandgren, J. A. Schroeder, T. H. Qui, R. D. Palmiter, R. I. Brinster, and D. C. Lee (1995). Inhibition of mammary gland involution is associated with TGFα but not c-myc induced tumorigenesis in transgenic mice. Cancer Res. 55:3915–3927.
G. D. Smith, R. Sharp, E. C. Kordon, C. Jhappan, and G. Merlino (1995). Transforming growth factor α promotes mammary tumorigenesis through selective survival and growth of secretory epithelial cells. Am J. Pathol. 147:1081–1096.
G. R. Merlo, D. Graus-Porta, N. Cella, B. M. Marte, D. Taverna, and N. E. Hynes (1996). Growth, differentiation and survival of HC11 mammary epithelial cells: Diverse effects of receptor tyrosine kinase-activating peptide growth factors. Eur. J. Cell Biol. 70:97–105.
L. T. Amundadottir, S. J. Nass, G. J. Berchem, M. D. Johnson, and R. B. Dickson (1996). Cooperation of TGFα and c-Myc mouse mammary tumorigenesis: coordinated stimulation of growth and suppression of apoptosis. Oncogene 13:757–765.
S. J. Nass, M. Li, L. T. Amundadottir, P. A. Furth, and R. B. Dickson (1996). Role for Bcl-xL in the regulation of apoptosis by EGF and TGFβ1 in c-myc overexpressing mammary epithelial cells. Biochem. Biophys. Res. Commun. 227: 248–256.
I. M. Krane and P. Leder (1996). NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene 12:1781–1788.
E. J. Ormerod and P. S. Rudland (1984). Cellular composition and organization of ductal buds in developing rat mammary glands: Evidence for morphological intermediates between epithelial and myoepithelial cells. Am. J. Anat. 170:631–652.
N. J. Kenney, R. Huang, G. Johnson, D. Okamura, W. Matheny, G. Plowman, G. H. Smith, D. S. Salomon, and E. D. Adamson (1995). Detection and localization of amphiregulin and cripto-1 in the developing mouse mammary gland. Mol. Reprod. Dev. 4:277–286.
P. W. Cook, M. Piepkorn, C. H. Clegg, G. D. Plowman, J. M. DeMay, J. R. Brown, and M. R. Pittelkow (1997). Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. J. Clin. Invest. 100:2286–2294.
K. J. Fowler, F. Walker, W. Alexander, M. L. Hibbs, E. C. Nice, R. M. Bohmer, G. B. Mann, C. Thumwood, R. Maglitto, J. A. Danks, R. Chetty, A.W. Burgess, and A.R. Dunn. (1995). A mutation in the epidermal growth factor receptor in waved-2 mice has a profound effect on receptor biochemistry that results in impaired lactation. Proc. Natl. Acad. Sci. U.S.A. 92: 1465–1469.
M. A. Helmrath, C. E. Shin, C. R. Erwin, and B. W. Warner (1998). The EGF-receptor axis modulates enterocyte apoptosis during intestinal adaptation. J. Surg. Res. 77:17–22.
D. I. Kitsberg and P. Leder (1996). Keratinocyte growth factor induces mammary gland and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice. Oncogene 13: 2507–2515.
C. G. Prosser (1996). Insulin-like growth factors in milk and mammary gland. J. Mam. Gland Biol. Neoplasia 1:297–306.
D. L. Kleinberg (1998). Role of IGF-1 in normal mammary development. Br. Cancer Res. Treatment 47:201–208.
G. L. Francis, F.M. Upton, F.J. Ballard, K.A. Mcneil, and J.C. Wallace (1988). Insulin-like growth factors 1 and 2 in bovine colostrum. Biochem. J. 251:95–103.
E. Tonner, L. Quarrie, M. Travers, M. Barber, A. Logan, C. Wilde, and D. Flint (1995). Does an IGF-binding protein (IGFBP) present in involuting rat mammary gland regulate apoptosis? Prog. Growth Factor Res. 6:409–414
E. Tonner, M. C. Barber, M. T. Travers, A. Logan, and D. J. Flint (1997). Hormonal control of insulin-like growth factorbinding protein-5 production in the involuting mammary gland of the rat. Endocrinology 138:5101–5107.
J. A. Mol, P. J. Selman, E. P. Sprang, J. W. van Neck, and M. A. Oosterlaken-Dijksterhuis (1997). The role of progestins, insulin-like growth factor (IGF) and IGF-binding proteins in the normal and neoplastic mammary gland of the bitch: A review. J. Reprod. Fertil. Suppl. 51:339–344.
R. S. Guenette and M. Tenniswood (1995). The role of insulinlike growth factor binding proteins (IGFBPs) in regulating active cell death in regressing rat prostate and mammary gland. J. Cell. Biochem. 19B:280.
T. Nickerson, M. Pollak, and H. Huynh (1998). Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2,3,4, and 5. Endocrinology 139:807–810.
X. J. Liu, M. Malkowski, Y. Guo, G. F. Erickson, S. Shimasaki, and F. Ling (1993). Development of specific antibodies to insulin-like growth factor binding proteins (IGFBP-2 to-6): Analysis of IGFBP production by rat granulosa cells. Endocrinology 132:1176–1183.
I. D. Phillips, G. P. Becks, A. Logan, J. F. Wang, C. Smith, and D. J. Hill (1994). Altered expression of insulin-like growth factor-1 (IGF-1) and IGF binding proteins during rat thyroid hyperplasia and involution. Growth Factors 10:207–222.
D. LeRoith, S. Neuenschwander, T. L. Wood, and L. Henninghausen (1995). Insulin-like growth factor-1 and Insulin-Like growth factor binding protein-3 inhibit involution of the mammary gland following lactation: Studies in transgenic mice. Prog. Growth Factor Res. 6:433–436.
S. Neuenschwander, A. Schwartz, T. L. Wood, C. T. L. Roberts, L. Henninghausen, and D. LeRoith (1996). Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model. J. Clin. Invest. 97:2225–2232.
M. Binoux and P. Hossenlopp (1988). Insulin-like growth factor (IGF) and IGF-binding proteins: comparison of human serum and lymph. J. Clin. Endocrinol. Metab. 67:509–514.
R. C. Baxter and J. L. Martin (1989). Binding proteins for the insulin-like growth factors: structure, regulation and function. Prog. Growth Factor Res. 1:49–68.
G. L. Francis, L. C. Read, F. J. Ballard, C. J. Bagley, F. M. Upton, P. M. Gravestock, and J. C. Wallace (1986). Purification and partial sequence analysis of insulin-like growth factor-1 from bovine colostrum. Biochem. J. 233:207–213.
Y. Oh, H. L. Muller, D. Y. Lee, P. J. Fielder, and R. G. Rosenfeld (1993). Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1–4 for IGF-1, IGF-II, IGF-I/Insulin hybrid, and IGF-1 analogs. Endocrinology 132: 1337–1344.
D. L. Hadsell, N. M. Greenberg, J. M. Fligger, C. R. Baumrucker, and J.M. Rosen (1988). Targeted expression of des (1–3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology 137:321–330.
G. B. Silbertstein and C. W. Daniel. (1987) Reversible inhibition of mammary gland growth by transforming growth factor β. Science 237:291–293.
C. L. Artega, T. C. Dugger, and S. D. Hurd (1996). The multifunctional role of transforming growth factor (TGF)-βs on mammary epithelial cell biology. Br. Cancer Res. Treat. 38: 49–56.
C. W. Daniel, S. Robinson, and G. B. Silberstein (1996). The role of TGF-β in patterning and growth of the mammary ductal tree. J. Mam. Gland Biol. Neoplasia 1:331–342.
C. S. Atwood, M. Ikeda, and B. K. Vonderhaar (1995). Involution of mouse mammary glands in whole organ culture: A model for studying programmed cell death. Biochem. Biophys. Res. Commun. 207:860–867.
D. F. Pierce, M. D. Johnson, Y. Matsui, S. D. Robinson, L. I. Gold, A. F. Purchio, C. W. Daniel, B. L. M. Hogan, and H. L. Moses (1993). Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGFβ1. Genes Dev. 7:2308–2317.
A. M. Brunner, H. Marquardt, A. R. Malacko, M. N. Lioubin, and A. F. Purchio (1989). Site directed mutagenesis of cysteine residues in the pro region of the transforming growth factor β-1 precursor. J. Biol. Chem. 264:13660–13664.
C. Jhappan, A. G. Geiser, E. C. Kordon, D. Bagheri, L. Hennighausen, A. B. Roberts, G. H. Smith, and G. Merlino (1993). Targeting expression of a transforming growth factor β1 transgene to the pregnant mammary gland inhibits alveolar development and lactation. EMBO J. 12:1835–1845.
E. C. Kordon, R. A. McKnight, C. Jhappan, L. Hennighausen, G. Merlino, and G. H. Smith (1995). Ectopic TGFβ1 expression in the secretory mammary epithelium induces early senescence of the epithelial stem cell population. Dev. Biol. 168:47–61.
D. K. Armstrong, J. T. Isaacs, Y. L. Ottaviano, and N. E. Davidson (1992). Programmed cell death in an estrogen-independent human breast cancer cell line, MDA-MB-468. Cancer Res. 52:3418–3424.
H. Chen, T. R. Tritton, N. Kenny, M. Absher, and J. F. Chiu (1996). Tamoxifen induces TGF-β1 activity and apoptosis of human MCF-7 breast cancer cells in vitro. J. Cell Biochem. 61:9–17.
A. A. Colletta, L. M. Wakefield, F. V. Howell, D. Danielpour, M. Baum, and M. B. Sporn (1991). The growth inhibition of human breast cancer cells by a novel synthetic progestin involves the induction of transforming growth factor beta. J. Clin. Invest. 87:277–283.
A. M. Warri, R. L. Huovinen, A. M. Laine, P. M. Martikainen, and P. L. Harkonen (1993). Apoptosis in toremifene induced growth inhibition of human breast cancer cells in vivo and in vitro. J. Natl. Cancer Institute. 85:1412–1418.
C. Knabbe, L. Wakefield, K. Flanders, A. Kasid, R. Derynk, M. E. Lippman, and R. B. Dickson (1987). Evidence that TGF beta is a hormonally regulated negative growth factor in human breast cancer. Cell 48:417–428.
J. R. Benson, M. Baum, and A. A. Colletta (1996). Role of TGFβ in the anti-estrogen response/resistance of human breast cancer. J. Mam. Gland Biol. Neoplasia 1:381–390.
A. Butta, K. MacLennan, K. C. Flanders, N. P. M Sacks, I. Smith, A. McKinna, M. Dowsett, L. M. Wakefield, M.B. Sporn, M. Baum, and A. A. Colletta (1992). Induction of transforming growth factor β1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res. 52:4261–4264.
J. R. Benson, L. M. Wakefield, M. Baum and A. A. Colletta (1996). Synthesis and secretion of transforming growth factor beta isoforms by primary cultures of human breast tumour fibroblasts in vitro and their modulation by tamoxifen. Brit. J Cancer 74:352–358.
R. R. Perry, Y. Kang, and B. R. Greaves (1995). Relationship between tamoxifen-induced transforming growth factor beta 1 expression, cytostasis and apoptosis in human breast cancer cells Brit. J. Cancer 72:1441–1446.
E. Kalkhoven, L. Kwakkenbos-Isbrucker, C. L. Mummery, S. W. de Laat, A. J. M. van den Eijnden-van Raaij, P. T. van der Saag, and B. van der Burg (1995). The role of TGF-β production in growth inhibition of breast-tumor cells by progestins. Int. J. Cancer 61:80–86.
E. Kalkhoven, B. A. J. Roelen, J. P. de Winter, C. L. Mummery, A. J. M. van den Eijnden-van Raaij, P. T. van der Saag, and B. van der Burg (1995). Resistance to transforming growth factor beta and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ. 6: 1151–1161.
K. M. Koli, T. T. Ramsey, Y. Ko, T. C. Dugger, M. G. Brattain, and C. L. Arteaga (1997). Blockade of transforming growth factor-β signaling does not abrogate antiestrogen-induced growth inhibition of human breast cancer cells. J. Biol. Chem. 272:8296–8302.
N. Sathyamoorthy, J. S. Gilsdorf, and T. T. Y. Wang (1998). Differential effect of genistein on transforming growth factor β1 expression in normal and malignant mammary epithelial cells. Anticancer Res. 18:2449–2453.
M. C. Pagliacci, M. Smacchia, G. Migliorati, F. Grignani, C. Riccardi, and I. Nicoletti (1994). Growth-inhibitory effects of the natural phyto-oestrogen genistein in MCF-7 human breast cancer cells. Eur. J. Cancer 30A:1675–1682.
M. Katdare, M. P. Osborne, and N. T. Telang (1998). Inhibition of aberrant proliferation and induction of apoptosis in preneoplastic human mammary epithelial cells by natural phytochemicals. Oncol. Rep. 5:311–315.
L. Fioravanti, V. Cappelletti, P. Miodini, E. Ronchi, M. Brivio, and G. Di Fronzo (1998). Genistein in the control of breast cancer cell growth: Insights into the mechanism of action in vitro. Cancer Lett. 130:143–152.
F. M. Uckun, R. K. Narla, X. Jun, T. Zeren, T. Venkatachalam, K. G. Waddick, A. Rostostev, and D. E. Myers (1998). Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells. Clin. Cancer Res. 4:901–912.
A. Geier, C. Weiss, R. Beery, M. Haimsohn, R. Hemi, Z. Malik, and A. Karasik (1995). Multiple pathways are involved in protection of MCF-7 cells against death due to protein synthesis inhibition. J. Cell Physiol. 163:570–576.
H. Aoyagi and R. B. Dickson (undated). Programmed cell death and its resistance in breast cancer chemotherapy. Pathogenesis (in press).
R. R. Beerli, D. Graus-Porta, K. Woods-Cook, X. Chen, Y. Yarden, and N. E. Hynes. (1995). Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol. Cell Biol. 15: 6496–6505.
C. C. Benz, G. K. Scott, J. C. Sarup, R. M. Johnson, D. Tripathy, E. Coronado, H. M. Shepard, and C. K. Osborne (1993). Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Br. Cancer Res. Treat. 24:85–95.
R. Kumar, M. Mandal, A. Lipton, H. Harvey, and C. B. Thompson (1996). Overexpression of HER2 Modulates Bcl-2, Bcl-XL, and tamoxifen induced apoptosis of human MCF-7 breast cancer cells. Clin. Cancer Res. 2:1215–1219.
J. M. Daly, C. B. Jannot, R. R. Beerli, D. Graus-Porta, F. G. Maurer, and N. E. Hynes (1997). Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2–overexpressing breast tumor cells. Cancer Res. 57:3804–3811.
G. Peters, S. Brookes, R. Smith, M. Placzek, and C. Dickson (1989). The mouse homolog of the hstlk-FGF gene is adjacent to int-2 and is activated by proviral insertion in some virally induced mammary tumors. Proc. Natl. Acad. Sci. U.S.A. 86: 5678–5682.
H. Wang, M. Rubin, E. Fenig, A. DeBlasio, J. Mendelsohn, J. Yahalom, and R. Wieder (1997). Basic fibroblast growth factor causes growth arrest in MCF-7 human breast cancer cells while inducing both mitogenic and inhibitory G1 events. Cancer Res. 57:1750–1757.
Q. Wang, P. Maloof, H. Wang, E. Fenig, D. Stein, G. Nichols, T. N. Denny, J. Yahalom, and R. Wieder (1998). Basic fibroblast growth factor downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells. Exp. Cell Res. 238:177–187.
L. Zhang, S. Kharbanda, J. Hanfelt, and F. G. Kern (1998). Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF-7 breast cancer cells. Cancer Res. 58:352–361.
H. Ueno, M. Gunn, K. Dell, A. Tseng, and L. Williams (1992). A truncated form of fibroblast growth factor receptor 1 inhibits signal transduction by multiple types of fibroblast growth factor receptor. J. Biol. Chem. 267:1470–1476.
T. Nickerson, H. Huynh, and M. Pollak (1997). Insuling-like rowth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. Biochem. Biophys. Res. Commun. 237: 690–693.
Z. P. Gill, C. M. Perks, P. V. Newcomb, and J. M. P. Holly (1997). Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J. Biol. Chem. 272:25602–25607.
E. A. Carswell, L. J. Old, R. L. Kassel, S. Green, N. Fiore, and B. Williamson (1975). An endotoxin-induc ed serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U.S.A. 72:3666–3670.
A. Ashkenazi and V. M. Dixit (1998). Death receptors: Signaling and modulation. Science 281:1305–1308.
B. J. Sugarman, B. B. Aggarwai, P. E. Haas, I. S. Figari, M. Palladino, and H. M. Shepard (1985). Recombinant human tumor necrosis factor-α: Effects on proliferation of normal and transformed cells in vitro. Science 230:943–945.
B. Sherry and A. Cerami (1988). Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses. J. Cell. Biol. 107:1269–1275.
G. T. Budd, S. Green, L. H. Baker, E. P. Hersh, J. K. Weick, and C. K. Osborne (1991). A southwest oncology group phase II trial of recombinant tumor necrosis factor in metastatic breast cancer. Cancer 68:1694–1695.
G. Bellomo, M. Perotti, F. Taddei, F. Mirabelli, G. Finardi, P. Nicotera, and S. Orrenius (1992). Tumor necrosis factor α induces apoptosis in mammary adenocarcinoma cells by an increase in intranuclear free Ca2+ concentration and DNA fragmentation. Cancer Res. 52:1342–1346.
M. Jaattela, M. Benedict, M. Tewari, J. A. Shayman, and V. M. Dixit (1995). Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene 10:2297–2305.
A. Srinivasan, F. Li, A. Wong, L. Kodandapani, R. Smidt, Jr., J. F. Krebs, L. C. Fritz, J. C. Wu, and K.J. Tomaselli (1998). Bcl-X L functions downstream of caspase-8 to inhibit Fas-and tumor necrosis factor receptor 1–induced apoptosis of MCF7 breast carcinoma cells. J. Biol. Chem. 273:4523–4529.
Rights and permissions
About this article
Cite this article
Rosfjord, E.C., Dickson, R.B. Growth Factors, Apoptosis, and Survival of Mammary Epithelial Cells. J Mammary Gland Biol Neoplasia 4, 229–237 (1999). https://doi.org/10.1023/A:1018789527533
Issue Date:
DOI: https://doi.org/10.1023/A:1018789527533